Editorial: El Mundo

• The new preliminary draft of the Medicines and Health Products Act, to be submitted to Parliament without consensus, has generated criticism from the industry and opposition.
• The project favors the sustainability of the system and access to medicines, but lacks dialogue.
• The industry rejects the auction system for non-patent medicine prices, considering that it encourages dumping and does not guarantee continuous supply.
• The Ministry seeks to contain spending on medicines, but must provide stability and certainty to the industry.

Conclusion: The challenge lies in optimizing the system without risking an essential sector.

---